Predicting poor outcome of pneumonia;Neumonía: Predecir la mala evolución

Archivos de Bronconeumologia

Volumn 41, Issue 9, 2005, Pages 475-477

  Menendez R ^a   Torres, A ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; CYTOKINE; HYDROCORTISONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROLIDE; TUMOR NECROSIS FACTOR ALPHA;

ANTIBIOTIC RESISTANCE; BACTERIAL PNEUMONIA; COMMUNITY ACQUIRED PNEUMONIA; EDITORIAL; HOSPITAL INFECTION; HUMAN; IMMUNE SYSTEM; MORTALITY; OUTCOMES RESEARCH; PNEUMONIA; PROGNOSIS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 26844556903     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13078647     Document Type: Editorial

References (25)

1. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA. 1999;281:61-6.
2. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996;275:134-41.
3. Ewig S, Ruiz M, Torres A, et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med. 1999;159:1835-42.
4. Aspa J, Rajas O, Rodríguez de Castro F, et al. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis. 2004;38:787-98.
5. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-50.
6. Lim WS, Van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377-82.
7. Menéndez R, Torres A, Zalacain R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax. 2004;59:960-5.
8. Kuru T, Lynch JP III. Nonresolving or slowly resolving pneumonia. Clin Chest Med. 1999;20:623-51.
9. Kirtland SH, Winterbauer RH. Slowly resolving, chronic, and recurrent pneumonia. Clin Chest Med. 1991;12:303-18.
10. Feinsilver SH, Fein AM, Niederman MS, Schultz DE, Faegenburg DH. Utility of fiberoptic bronchoscopy in nonresolving pneumonia. Chest. 1990;98:1322-6.
11. Fein AM, Feinsilver SH, Niederman MS. Nonresolving and slowly resolving pneumonia. Diagnosis and management in the elderly patient. Clin Chest Med. 1993;14:555-69.
12. Montravers P, Fagon JY, Chastre J, et al. Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis. 1993;147:38-44.
13. Arancibia F, Ewig S, Martínez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med. 2000; 162:154-60.
14. Roson B, Carratalá J, Fernández-Sabe N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med. 2004;164:502-8.
15. Menéndez R, Ferrando D, Vallés JM, Vallterra J. Influence of deviation from guidelines on the outcome of community-acquired pneumonia. Chest. 2002;122:612-7.
16. Bonten MJ, Froon AH, Gaillard CA, et al. The systemic inflammatory response in the development of ventilator-associated pneumonia. Am J Respir Crit Care Med. 1997;156(4 Pt 1):1105-13.
17. Nelson S. Novel nonantibiotic therapies for pneumonia: cytokines and host defense. Chest. 2001;119 Suppl 2:419-25.
18. Skerrett SJ, Park DR. Anti-inflammatory treatment of acute and chronic pneumonia. Semin Respir Infect. 2001;16:76-84.
19. Monton C, Torres A, El-Ebiary M, Filella X, Xaubet A, De la Bellacasa JP. Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit Care Med. 1999;27:1745-53.
20. Ioanas M, Ferrer R, Ferrer M, et al. Causes and predictors of treatment failure in patients with ICU-acquired pneumonia. Eur Respir J. 2002;20 Suppl 38:16.
21. Waterer GW, Quasney MW, Cantor RM, Wunderink RG. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med. 2001;163:1599-604.
22. Luyt CE, Guerin V, Combes A, et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med. 2005;171:48-53.
23. Monton C, Ewig S, Torres A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J. 1999;14:218-20.
24. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2004;19:19.
25. Amsden GW. Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother. 2005;55:10-21.